Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Chengdu Brilliant Pharmaceutical Co. Ltd. and Chengdu Xinke Pharmaceutical Co. Ltd. have disclosed drug conjugates comprising a bone-targeting moiety covalently bound to a radiolabeled-chelating agent ...

Reston, VA (October 13, 2025)--A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during ...

Please provide your email address to receive an email when new articles are posted on . DocGo and Spect have partnered to provide mobile health clinicians a more cost-effective way to screen patients ...

Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...